Natural human Plasminogen protein (FITC) (ab92770)

Overview

Description

  • Nature
    Native
  • Source
    Native
  • Amino Acid Sequence
    • Species
      Human
  • Conjugation
    FITC. Ex: 493nm, Em: 528nm

Specifications

Our Abpromise guarantee covers the use of ab92770 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activity
    Activity: No plasmin activity detected with the chromogenic substrate S-2251. > 98% conversion to plasmin is observed upon activation with uPA.
  • Applications

    SDS-PAGE

  • Purity
    > 95 % SDS-PAGE.

  • Form
    Liquid
  • Additional notes
    Protect from light.
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 0.1M Sodium chloride, 0.1M HEPES, pH 7.4

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • Angiostatin
    • DKFZp779M0222
    • Plasmin
    • Plasmin heavy chain A
    • Plasmin light chain B
    • Plasminogen
    • PLG
    • PLMN_HUMAN
    see all
  • Function
    Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.
    Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.
  • Tissue specificity
    Present in plasma and many other extracellular fluids. It is synthesized in the liver.
  • Involvement in disease
    Defects in PLG are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
    Defects in PLG are the cause of plasminogen deficiency (PLGD) [MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa.
  • Sequence similarities
    Belongs to the peptidase S1 family. Plasminogen subfamily.
    Contains 5 kringle domains.
    Contains 1 PAN domain.
    Contains 1 peptidase S1 domain.
  • Domain
    Kringle domains mediate interaction with CSPG4.
  • Post-translational
    modifications
    N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).
    In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
  • Cellular localization
    Secreted. Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface.
  • Information by UniProt

References

ab92770 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Suite à votre appel, voici les renseignements que j'ai obtenus pour les produits ab76661, ab92544 et ab92770 :

ab92770 : cette protéine a une concentration de 1.8 mg/ml, le volume est donc de 0.560 ml. Il n'est pas nécessaire de dialyser cett...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up